Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Get Free Report) gapped up before the market opened on Tuesday after Truist Financial raised their price target on the stock from $36.00 to $41.00. The stock had previously closed at $37.39, but opened at $39.38. Truist Financial currently has a buy rating on the stock. Agios Pharmaceuticals shares last traded at $42.4870, with a volume of 383,278 shares.
AGIO has been the topic of a number of other research reports. Bank of America lifted their price objective on Agios Pharmaceuticals from $40.00 to $46.00 and gave the company a “buy” rating in a report on Tuesday. HC Wainwright decreased their price target on Agios Pharmaceuticals from $65.00 to $50.00 and set a “buy” rating on the stock in a research note on Monday, April 20th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Agios Pharmaceuticals in a report on Wednesday, June 24th. Wall Street Zen raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, March 22nd. Finally, JPMorgan Chase & Co. reduced their target price on Agios Pharmaceuticals from $36.00 to $31.00 and set a “neutral” rating for the company in a report on Thursday, June 11th. Six investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Agios Pharmaceuticals has an average rating of “Hold” and a consensus price target of $42.56.
Read Our Latest Analysis on Agios Pharmaceuticals
Institutional Inflows and Outflows
Agios Pharmaceuticals Stock Up 11.6%
The stock has a market capitalization of $2.48 billion, a PE ratio of -5.75 and a beta of 0.54. The business’s fifty day moving average is $30.43 and its 200-day moving average is $29.41.
Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) last released its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported ($1.69) EPS for the quarter, topping analysts’ consensus estimates of ($1.81) by $0.12. Agios Pharmaceuticals had a negative return on equity of 34.11% and a negative net margin of 639.84%.The business had revenue of $20.75 million during the quarter, compared to the consensus estimate of $13.30 million. The firm’s revenue was up 137.7% on a year-over-year basis. As a group, sell-side analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.28 EPS for the current fiscal year.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.
Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.
Featured Articles
- Five stocks we like better than Agios Pharmaceuticals
- GE Vernova’s Power Surge Turns the Grid Into an AI Trade
- Orbiting Capital: Lawmakers Buy SpaceX Ahead of Index Inclusion
- Big Beautiful Boycott: Can It Really Hurt Coca-Cola, Amazon, and Kraft Heinz Stocks?
- 3 Stocks With Solid Yields and Sustainabale Payouts Boost Dividends Once Again
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
